Insulet | PODD - Operating Profit


Insulet reported $189.8M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Abbott USD 1.36B 775M Sep/2026
Align Technology USD 193.04M 1.72M Sep/2026
AtriCure USD 4.35M 5.31M Sep/2026
Baxter International USD 314M 38M Sep/2026
Becton, Dickinson and Co. USD 752M 125M Jun/2026
Boston Scientific USD 1.01B 232M Sep/2026
Cardinal Health USD 814M 47M Jun/2026
Cooper Companies USD 222M 253M Jun/2026
Dexcom USD 318.3M 63M Jun/2026
Edwards Lifesciences USD 519.5M 4.8M Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Globus Medical USD -45.97M 209.97M Jun/2026
ICU Medical USD 60.43M 30.05M Jun/2026
Inogen USD -7.79M 728K Sep/2024
Insulet USD 189.8M 60.1M Sep/2026
Integra LifeSciences USD 42.65M 1.36M Sep/2026
J&J USD 6.47B 1B Sep/2026
Medtronic USD 1.84B 254M Jun/2026
Merit Medical Systems USD 60.4M 16.25M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Solventum Corp USD 181M 96M Jun/2026
Stryker USD 1.79B 687M Jun/2026
Tandem Diabetes Care USD -13.79M 3.64M Jun/2026
Teleflex USD 73.07M 36.04M Jun/2026
West Pharmaceutical Services USD -199.7M 378.8M Sep/2026
Zimmer Biomet Holdings USD 344.7M 50.4M Jun/2026